Stomach Cancer and Gastric Cancer Treatment Market Report 2025 (Global Edition)

Global Stomach Cancer and Gastric Cancer Treatment Market Report 2024 Market Size Split by Type (Chemotherapy, Immunotherapy, Targeted therapy, Radiation therapy and Surgery), by Disease Indication (G...

Stomach Cancer and Gastric Cancer Treatment Market Report Description

We have various report editions of Stomach Cancer and Gastric Cancer Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Stomach Cancer and Gastric Cancer Treatment Market Insights Video

Competitive Landscape of the Stomach Cancer and Gastric Cancer Treatment Market

In the competitive landscape of the Stomach Cancer and Gastric Cancer Treatment market, a variety of factors shape the dynamics. Leading pharmaceutical companies, research institutions, and healthcare service providers all over the world develop and commercialize treatment options, competing through novel therapies and heavy investments in research and development, as well as strategic partnerships to better one's market presence. With an increasing interest in personalized medicine, advancements in immunotherapy, targeted therapies, and other precision oncology approaches, the market is characterized by this. Hence, innovation and collaboration set a base that shapes the competitive nature of the stomach and gastric cancer treatment market

March 2022, Celltrion Healthcare stated that it has received a tender from the Brazilian Federal Government to buy Remsima (infliximab), the world's first monoclonal antibody biosimilar. In addition, the company won 12 state bids in Brazil to supply Remsima, including the largest state, Sao Paulo. (Source: https://www.biosimilardevelopment.com/doc/celltrion-healthcare-wins-tender-to-supply-remsima-to-the-brazilian-government-0001) February 2023, Pfizer formed a relationship with Tempus, a technology startup dedicated to developing precision medicine through the practical application of artificial intelligence in healthcare. Following the collaboration, Pfizer would gain access to Tempus' AI-powered platform and multimodal data repository, as well as its clinical trial matching program and companion diagnostic development capabilities. (Source: https://www.tempus.com/news/tempus-announces-new-strategic-collaboration-with-pfizer-to-advance-oncology-therapeutic-development/)

Top Companies Market Share in Stomach Cancer and Gastric Cancer Treatment Industry: (In no particular order of Rank)

• Novartis AG
• Pfizer
• Inc.
• Mylan N.V.
• F. Hoffmann La Roche Ltd.
• Eli Lilly And Company
• Merck & Co.
• Inc.
• Teva Pharmaceutical Industries Ltd.
• Celltrion Healthcare Co.
• Ltd.
• Samsung Bioepis
• Bristol Myers Squibb Company
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Stomach Cancer and Gastric Cancer Treatment Market

Which Region Dominates the Stomach Cancer and Gastric Cancer Treatment Market in 2024?

According to Cognitive Market Research, North America is the largest worldwide stomach cancer market shareholder and is predicted to grow significantly during the forecast period. The North American stomach cancer market is developing as a result of the growing number of specialty clinics and hospitals that provide cancer treatment, the availability of new technologies, and the prevalence of stomach cancer.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Stomach Cancer and Gastric Cancer Treatment market due to several compelling reasons. ?The rising elderly population in Asia-Pacific is driving market growth. The high prevalence of gastrointestinal cancers and lymphomas has fueled need for gastric cancer diagnostics. Furthermore, the increased prevalence of stomach cancer in the region is expected to drive market growth in Asia Pacific over the forecast period.

The current report Scope analyzes Stomach Cancer and Gastric Cancer Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Stomach Cancer and Gastric Cancer Treatment

According to Cognitive Market Research, the global Stomach Cancer and Gastric Cancer Treatment market size was estimated at USD 4124.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1649.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Stomach Cancer and Gastric Cancer Treatment market with a market size of USD 1301.60 million in 2024 and is projected to grow at a CAGR of 11.2% during the forecast period. The country's robust healthcare infrastructure, strong research and development capabilities, and high levels of healthcare expenditure have positioned it as a key player in advancing treatments for stomach and gastric cancers.
• The Canada Stomach Cancer and Gastric Cancer Treatment market had a market share of USD 197.96 million in 2024 and is projected to grow at a CAGR of 12.2% during the forecast period. Canada's healthcare system, research institutions, and pharmaceutical industry play a vital role in developing innovative treatment options for stomach and gastric cancers.
• The Mexico Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 11.9% during the forecast period, with a market size of USD 150.12 million in 2024.

Europe Stomach Cancer and Gastric Cancer Treatment

According to Cognitive Market Research, the global Stomach Cancer and Gastric Cancer Treatment market size was estimated at USD 4124.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 1237.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2031.

• The United Kingdom Stomach Cancer and Gastric Cancer Treatment market had a market share of USD 207.86 million in 2024 and is projected to grow at a CAGR of 12.5% during the forecast period. In the UK, Stomach Cancer and Gastric Cancer Treatment sales witness an upswing due to the advancements in medical research and technology.
• The France Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 10.9% during the forecast period, with a market size of USD 113.83 million in 2024.
• According to Cognitive Market Research, the Germany Stomach Cancer and Gastric Cancer Treatment market size was valued at USD 244.98 million in 2024 and is projected to grow at a CAGR of 11.9% during the forecast period. In Germany, Stomach Cancer and Gastric Cancer Treatment sales surged due to the availability of cutting-edge treatment options.
• The Italy Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 106.40 million in 2024.
• The Russia Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 191.78 million in 2024.
• The Spain Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 10.8% during the forecast period with a market size of USD 101.46 million in 2024
• The Luxembourg Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 11.8% during the forecast period, with a market size of USD 38.36 million in 2024.
• The Portugal Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 25.98 million in 2024.

Asia Pacific Stomach Cancer and Gastric Cancer Treatment

According to Cognitive Market Research, the global Stomach Cancer and Gastric Cancer Treatment market size was estimated at USD 4124.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 948.57 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.2% from 2024 to 2031

• According to Cognitive Market Research, the China Stomach Cancer and Gastric Cancer Treatment market size was valued at USD 426.85 million in 2024 and is projected to grow at a CAGR of 14.7% during the forecast period. Stomach Cancer and Gastric Cancer Treatment sales surge in China due to increasing awareness about early cancer detection.
• The Japan Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 130.90 million in 2024.
• The India Stomach Cancer and Gastric Cancer Treatment market had a market share of USD 113.83 million in 2024 and is projected to grow at a CAGR of 17.0% during the forecast period. India's advancements in treatment options have all contributed to the expansion of the market.
• The South Korea Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 14.3% during the forecast period, with a market size of USD 94.86 million in 2024.
• The Australia Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 49.33 million in 2024.
• The South East Asia Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 16.2% during the forecast period, with a market size of USD 65.45 million in 2024.
• The Rest of Asia Pacific Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 15.0% during the forecast period, with a market size of USD 67.35 million in 2024.

South America Stomach Cancer and Gastric Cancer Treatment

According to Cognitive Market Research, the global Stomach Cancer and Gastric Cancer Treatment market size was estimated at USD 4124.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 206.21 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Stomach Cancer and Gastric Cancer Treatment market size was valued at USD 88.26 million in 2024 and is projected to grow at a CAGR of 13.2% during the forecast period. Stomach Cancer and Gastric Cancer Treatment sales flourish in Brazil due to the improved diagnostic techniques.
• Argentina Stomach Cancer and Gastric Cancer Treatment market had a market share of USD 34.64 million in 2024 and is projected to grow at a CAGR of 13.5% during the forecast period. The country's focus is on improving healthcare infrastructure.
• Colombia Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 12.4% during the forecast period with a market size of USD 18.35 million in 2024.
• Peru Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 12.8% during the forecast period with a market size of USD 16.91 million in 2024.
• Chile Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 12.9% during the forecast period with a market size of USD 14.85 million in 2024.
• The Rest of Latin America Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 33.20 million in 2024.

Middle East and Africa Stomach Cancer and Gastric Cancer Treatment

According to Cognitive Market Research, the global Stomach Cancer and Gastric Cancer Treatment market size was estimated at USD 4124.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 82.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031.

• The GCC Countries Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 13.7% during the forecast period with a market size of USD 35.30 million in 2024. Stomach Cancer and Gastric Cancer Treatment sales flourish due to personalized medicine approaches have contributed to the rise in treatment sales.
• The Egypt Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 13.2% during the forecast period, with a market size of USD 8.66 million in 2024.
• The South Africa Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 13.03 million in 2024. Stomach Cancer and Gastric Cancer Treatment sales flourish in South Africa due to the improvements in healthcare infrastructure.
• The Turkey Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 12.4% during the forecast period, with a market size of USD 7.09 million in 2024.
• The Nigeria Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 12.0% during the forecast period, with a market size of USD 8.66 million in 2024.
• The Rest of MEA Stomach Cancer and Gastric Cancer Treatment market is projected to witness growth at a CAGR of 11.9% during the forecast period, with a market size of USD 9.73 million in 2024.

Stomach Cancer and Gastric Cancer Treatment Market Analysis

Global Stomach Cancer and Gastric Cancer Treatment Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Stomach Cancer and Gastric Cancer Treatment Industry growth. Stomach Cancer and Gastric Cancer Treatment market has been segmented with the help of its Type, Disease Indication Drug Class, and others. Stomach Cancer and Gastric Cancer Treatment market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Stomach Cancer and Gastric Cancer Treatment Market Type Segment Analysis

According to Cognitive Market Research, in 2023, the chemotherapy category accounted for the greatest revenue share of the gastric cancer therapy market due to the high prescription rate. Surgery with adjuvant or neoadjuvant chemotherapy is typically the first-line treatment for patients diagnosed in the early stages. According to one report, approximately 65% of patients with advanced malignancies, 85% with lymph node metastases, and 40% with metastatic disease require surgical operations. Chemotherapy can be used as neoadjuvant or adjuvant therapy to reduce the tumor or kill malignant cells. The market is divided into three segments based on treatment type: chemotherapy, immunotherapy, and targeted therapy.

Targeted therapy is the fastest-growing category in the Stomach Cancer and Gastric Cancer Treatment market, owing to product releases, recent advances in the field of targeted therapy, and a strong clinical pipeline. However, the patent expiration of Herceptin is limiting the expansion of this segment.

Stomach Cancer and Gastric Cancer Treatment Market Share (%) by Type in 2019-2031

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Stomach Cancer and Gastric Cancer Treatment Industry. Request a Free Sample PDF!

Stomach Cancer and Gastric Cancer Treatment Market Disease Indication Category Segment Analysis

According to Cognitive Market Research, the Gastric Cancer/Gastroesophageal Junction Cancer category had the highest revenue share in 2023. The significant disease burden, combined with a wide number of authorized medications for this indication, is driving the segment's expansion. According to Globocan, the 5-year prevalence of stomach cancer was around 1.8 million in 2020. The market is divided into two segments based on illness indications: gastric cancer/gastroesophageal junction cancer (GC/GEJC) and gastrointestinal stromal tumors.

The gastrointestinal stromal tumors (GISTs) segment is expected to develop moderately throughout the forecast period. GISTs are rare malignancies, with approximately 4,000 to 6,000 new cases identified annually in the United States. GISTs are treated using targeted medications such as Ayvakit, Gleevec, Stivarga, and Qinlock.

Stomach Cancer and Gastric Cancer Treatment Market Share (%) by Disease Indication in 2019-2031

2019

2023

2031

The above Graph is for representation purposes only. This chart does not depict actual Market share.

To learn more about market share request the free sample pages.

Get Free Sample

Stomach Cancer and Gastric Cancer Treatment Drug Class Segment Analysis

Drug Class Segment Analysis

According to Cognitive Market Research, In 2023, the PD-1/PD-L1 inhibitors category dominated the gastric cancer market with the highest revenue share. Immune checkpoint proteins like programmed cell death protein 1 (PD-1) and PD-L1 frequently help avoid hyperactive immune responses that can harm healthy tissues. Several PD-1/PD-L1 inhibitors, including nivolumab, pembrolizumab, and atezolizumab, have been approved for the treatment of advanced or metastatic gastric cancer. Several treatments have been shown in people with advanced stomach cancer to improve survival and reduce tumor development.

The HER2 antagonists segment is projected to be the fastest-growing. The HER2 antagonists target human epidermal growth factor receptor 2, a protein that can cause the growth of cancer cells. The treatment for stomach and gastric cancers, which are HER2 gene positive, has gained substantial acceptance in the past years due to considerable efficacy shown by HER2-targeted therapies; this has boosted the growth of this segment.

• PD-1/PD-L1 inhibitors
• HER2 antagonists
• VEGFR2 antagonists
• Others

Stomach Cancer and Gastric Cancer Treatment Route of Administration Segment Analysis

Route of Administration Segment Analysis

According to Cognitive Market Research, in 2023, the injectable segment led the gastric cancer therapy market, accounting for more than 90.09% of revenues. The majority of chemotherapy medications, targeted drugs, and immunotherapy drugs are available in injectable form, which accounts for this segment's dominance.

The oral segment is predicted to develop at the fastest rate over the projection period. Many businesses are developing oral chemotherapy medicines to alleviate the burden of IV delivery. For example, Ascelia Pharma is now undertaking Phase II clinical trials for Oncoral (oral irinotecan) to treat gastric cancer.

• Oral
• Injectable

Stomach Cancer and Gastric Cancer Treatment Distribution Channel Segment Analysis

Distribution Channel Segment Analysis

According to Cognitive Market Research, in 2023, specialty and retail pharmacies controlled the gastric cancer therapy market. Most medications used to treat stomach cancer are delivered through specialized pharmacies because they must be stored and distributed under certain circumstances.

Hospital pharmacies will be the market's fastest-expanding sector in 2023. The establishment of government-sponsored hospital pharmacies, as well as favorable reimbursement, are the primary drivers of the hospital pharmacy segment's expansion. These are the reasons behind the government's substantial support for cancer treatment. The category is also expected to grow as a result of an expanding patient pool, rising stomach cancer prevalence, and an increase in the number of cancer treatment centers

• Hospital Pharmacies
• Specialty & Retail Pharmacies
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Bio :

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.

In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.

Read More




Author's Conclusion

Conclusion

• The global Stomach Cancer and Gastric Cancer Treatment market will expand significantly by 13.20% CAGR between 2024 to 2031.
• Chemotherapy led the gastric cancer therapy market in terms of revenue due to its high prescription rate. Surgery with adjuvant or neoadjuvant chemotherapy is often the first-line treatment for individuals diagnosed in the early stage.
• The PD-1/PD-L1 inhibitor category dominated the gastric cancer market. Immune checkpoint proteins, such as programmed cell death protein 1 (PD-1) and PD-L1, are routinely used to prevent excessive immune responses that can harm healthy tissues. Several PD-1/PD-L1 inhibitors, including nivolumab, pembrolizumab, and atezolizumab, are licensed for the treatment of advanced or metastatic gastric cancer.

Frequently Asked Questions (FAQs)

What is the market size for the Stomach Cancer and Gastric Cancer Treatment market in 2024?

The global market size for Stomach Cancer and Gastric Cancer Treatment in 2024 is USD 4124.2 million.

What is the growth rate for the Stomach Cancer and Gastric Cancer Treatment market over the forecast period?

The global Stomach Cancer and Gastric Cancer Treatment market is expected to grow with a CAGR of 13.20% over the projected period.

Which is the leading region of the market for Stomach Cancer and Gastric Cancer Treatment?

North America held a significant global Stomach Cancer and Gastric Cancer Treatment market revenue share in 2024.

Which region is projected to detect the fastest growth in the Stomach Cancer and Gastric Cancer Treatment market over the forecast period?

Asia-Pacific will witness the fastest growth of the global Stomach Cancer and Gastric Cancer Treatment market over the coming years.

Which country is leading in the Stomach Cancer and Gastric Cancer Treatment market in 2024?

The US had the most significant global Stomach Cancer and Gastric Cancer Treatment market revenue share in 2024.

What are the key drivers for the growth of the Stomach Cancer and Gastric Cancer Treatment market?

The main drivers of the growth of the Stomach Cancer and Gastric Cancer Treatment market are increased incidence of stomach cancer, improved healthcare infrastructure, and advances in medical research

Which is the significant Stomach Cancer and Gastric Cancer Treatment market segment by Distribution Channel?

Specialty and retail pharmacies controlled the gastric cancer therapy market.